⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18788132 | 0.78 | LPO (0.33) | — | |
| SCHEMBL14194705 | 0.75 | PLAT (0.44) | — | |
| SCHEMBL24792211 | 0.75 | XDH (0.31) | — | |
| SCHEMBL20971707 | 0.71 | ALDH1A1 (0.31) | — | |
| SCHEMBL21483570 | 0.70 | PLAT (0.36) | — | |
| SCHEMBL27223068 | 0.68 | POLB (0.34) | — | |
| SCHEMBL23529884 | 0.68 | XDH (0.36) | — | |
| SCHEMBL24408250 | 0.67 | HAVCR2 (0.35) | — | |
| SCHEMBL18510365 | 0.67 | CDK7 (0.34) | — | |
| SCHEMBL15224509 | 0.65 | LMNA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220144839-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| WO-2020081636-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-9567345-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2017-02-14 | — | — | US | disclosed |
| EP-2820020-B1 | PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2820020-B1 | PYRAZOLO-TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN-DEPENDENT KINASE INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9096608-B2 | Pharmaceutically active pyrazolo-triazine derivatives | LEAD DISCOVERY CENTER GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-23 | — | — | US | disclosed |
| US-20150111873-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2015-04-23 | — | — | US | disclosed |
| WO-2013128029-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013128028-A1 | PYRAZOLO - TRIAZINE DERIVATIVES AS SELECTIVE CYCLIN- DEPENDENT KINASE INHINITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2013-09-06 | — | — | WO | disclosed |
| EP-2634190-A1 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors | Lead Discovery Center GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2634190-A1 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors | Lead Discovery Center GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2634189-A1 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors | Lead Discovery Center GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2634189-A1 | Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors | Lead Discovery Center GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |